TG Therapeutics, Inc. (TGTX)

Market Cap	7.64B +51.4%
Revenue (ttm)	799.54M +76.1%
Net Income	441.49M +630.2%
EPS	2.77 +667.5%
Shares Out	141.85M
PE Ratio	19.46
Forward PE	28.44
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,368,582
Open	55.71
Previous Close	55.39
Day's Range	53.47 - 56.26
52-Week Range	26.76 - 59.30
Beta	1.66
Analysts	Buy
Price Target	69.71 (+29.36%)
Earnings Date	Nov 2, 2026

About TGTX

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Ublituximab ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 14, 1995
• Employees: 399
• Stock Exchange: NASDAQ
• Ticker Symbol: TGTX
• Website: https://www.tgtherapeutics.com

Financial Performance

In 2025, TG Therapeutics's revenue was $616.29 million, an increase of 87.32% compared to the previous year's $329.00 million. Earnings were $447.18 million, an increase of 1812.41%.

Analyst Summary

According to 8 analysts, the average rating for TGTX stock is "Buy." The 12-month stock price target is $69.71, which is an increase of 29.36% from the latest price.

Price Target

$69.71

(29.36% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Sep 12, 2026

Data Sources Report a data error